F-star Therapeutics Ltd., a clinical-stage immuno-oncology company focused on transforming the lives of patients with cancer through the development of innovative tetravalent bispecific (mAb 2 ™) antibodies, today announced that it will present two posters at the Society for Immunotherapy of Cancer’s (SITC)
| CAMBRIDGE, England and CAMBRIDGE, Mass., Oct. 22, 2020 /PRNewswire/ -- f-Star Ltd., a clinical-stage immuno-oncology company focused on transforming the lives of patients with cancer through the development of innovative tetravalent bispecific (mAb2™) antibodies, today announced that it will present two posters at the Society for Immunotherapy of Cancer’s (SITC) 35th Virtual Annual Meeting being held from Monday, November 9, 2020 to Saturday, November 14, 2020.
The posters will focus on FS118, F-star’s potentially first-in-class, tetravalent bispecific antibody that simultaneously blocks both the LAG-3 and PD-L1 immunosuppressive pathways. FS118 has preclinically and, in preliminary clinical data, demonstrated potent anti-tumor growth activity as well as a highly differentiated mechanism of action when compared to checkpoint monotherapies alone or in combinations. Abstracts are available on the SITC website and the accompanying posters will be available in the Virtual Poster Hall open from 8:00 am EST on Monday, November 9, until the Virtual Poster Hall closes on December 31, 2020. Details of the poster presentations: Title: A First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1, in Patients with Advanced Cancer and Resistance to PD-(L)1 Therapy Title: FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1, Induces LAG-3 Shedding Resulting in Receptor Downregulation by T Cells via a Novel mechanism of Action About F-star Therapeutics Ltd F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the Company’s goal is to offer patients greater and more durable benefits than current immuno-oncology treatments. Through its proprietary tetravalent, bispecific antibody (mAb²™) format, F-star’s mission is to generate highly differentiated best-in-class drug candidates with monoclonal antibody-like manufacturability. For more information visit www.f-star.com. For further information, please contact: For investor inquiries For media inquiries
SOURCE F-star Therapeutics Ltd. |
View original content to download multimedia:
